Spyre Therapeutics (SYRE) Equity Average (2016 - 2025)
Spyre Therapeutics (SYRE) has disclosed Equity Average for 10 consecutive years, with $585.2 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Equity Average rose 38.47% year-over-year to $585.2 million, compared with a TTM value of $585.2 million through Dec 2025, up 38.47%, and an annual FY2025 reading of $616.5 million, up 75.69% over the prior year.
- Equity Average was $585.2 million for Q4 2025 at Spyre Therapeutics, up from $455.4 million in the prior quarter.
- Across five years, Equity Average topped out at $585.2 million in Q4 2025 and bottomed at -$226.4 million in Q3 2023.
- Average Equity Average over 5 years is $182.5 million, with a median of $116.0 million recorded in 2021.
- The sharpest move saw Equity Average crashed 398.44% in 2023, then soared 1476.85% in 2024.
- Year by year, Equity Average stood at $93.0 million in 2021, then crashed by 36.64% to $58.9 million in 2022, then crashed by 152.08% to -$30.7 million in 2023, then skyrocketed by 1476.85% to $422.6 million in 2024, then surged by 38.47% to $585.2 million in 2025.
- Business Quant data shows Equity Average for SYRE at $585.2 million in Q4 2025, $455.4 million in Q3 2025, and $469.2 million in Q2 2025.